

Kind Attention: Mr. S. Subramanian, DCS-CRD

30-01-2016

To,  
The Stock Exchange, Mumbai  
P. J. Towers, Dalal Street  
Mumbai - 400 023.

Dear Sir,

Sub : Quarterly Results ( Subjected to Limited Review by the Auditors )  
Ref : Code of the Company - 531210 / COLINZ LABOR

As per clause 41 of the Listing Agreement, we are sending herewith the financial results (Subjected to Limited Review by the Auditors) for the quarter ended 31<sup>st</sup> December, 2015. Which has been taken on record in the Board meeting held on 30-01-2016.

Thanking you,

Yours faithfully,  
For COLINZ LABORATORIES LTD.,

  
Compliance Officer.

carried on 30/1/16

## COLINZ LABORATORIES LIMITED.

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078.

(CIN NO : L24200MH1986PLC041128)

UN-AUDITED RESULTS FOR THE THIRD QUARTER ENDED : 31st DECEMBER, 2015

(Rupees in " 000")

S. No.	Particulars	Un -audited			Un -audited		Audited
		Quarter ended			Nine Month Ended		Year
		31-Dec-15	30-Sep-15	31-Dec-14	31-Dec-15	31-Dec-14	31-Mar-15
<b>PART -I</b>							
1	<b>(a)Income from Operation</b>						
	Gross Sales	19,352	20,291	18,993	64,443	64,244	82,112
	Less Excise Duty	525	647	462	1,858	2,447	3,255
	<b>Net Sales/Income From Operation</b>	<b>18,827</b>	<b>19,644</b>	<b>18,531</b>	<b>62,585</b>	<b>61,797</b>	<b>78,857</b>
	(b) Other Operating Income	-	-	-	-	-	-
	<b>Total Income from Operation</b>	<b>18,827</b>	<b>19,644</b>	<b>18,531</b>	<b>62,585</b>	<b>61,797</b>	<b>78,857</b>
2	<b>Expenditure</b>						
	(a) Cost Of Material Consumed	3,601	3,346	3,081	11,127	12,216	16,372
	(b) Purchase of Goods Traded	2,363	4,534	4,914	8,555	18,463	27,076
	(c) (Increase)/Decrease in stock in trade	1,598	(109)	(1,426)	7,598	(3,718)	(9,795)
	(d) Staff Cost	7,175	7,536	7,903	22,001	22,015	27,663
	(e) Depreciation	703	702	655	2,107	1,965	2,975
	(f) Other Expenditure	3,049	3,300	2,930	9,831	9,543	13,063
	<b>Total Expenditure</b>	<b>18,489</b>	<b>19,309</b>	<b>18,057</b>	<b>61,219</b>	<b>60,484</b>	<b>77,354</b>
3	<b>Profit /(Loss) from Operation Before Other Income ( 1-2)</b>	<b>338</b>	<b>335</b>	<b>474</b>	<b>1,366</b>	<b>1,313</b>	<b>1,503</b>
4	Other Income/(Loss)	221	302	274	685	786	1,103
5	<b>Profit /Loss before Interest &amp; Exceptional items (3+4)</b>	<b>559</b>	<b>637</b>	<b>748</b>	<b>2,051</b>	<b>2,099</b>	<b>2,606</b>
6	Interest	271	260	391	869	824	1,151
7	<b>Profit /Loss after Interest but before exceptional items (5-6)</b>	<b>288</b>	<b>377</b>	<b>357</b>	<b>1,182</b>	<b>1,275</b>	<b>1,455</b>
8	Exceptional items	-	-	-	-	-	-
9	<b>Profit /Loss before Tax (7-8)</b>	<b>288</b>	<b>377</b>	<b>357</b>	<b>1,182</b>	<b>1,275</b>	<b>1,455</b>
10	Tax Expenses ( Provision for Taxation ) Current tax	(40)	(75)	(60)	(195)	(195)	(267)
	Deffered tax	(50)	(95)	(65)	(195)	(195)	(223)
11	<b>Net Profit/Loss after Tax (9-10)</b>	<b>198</b>	<b>207</b>	<b>232</b>	<b>792</b>	<b>885</b>	<b>965</b>
12	Paid up Equity Share Capital ( Face Value 10/- Per Share ) [Net of allotment money in arrears]	354,41	354,39	354,35	354,41	354,35	354,39
13	Reserves Excluding Revaluation Reserves	-	-	-	-	-	7,470
14	Earning per share (EPS) before extraordinary item( not Annualised)	-	-	-	-	-	-
	i) Basic & Diluted						0.21
	ii) Diluted						
<b>PART -II</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
1	<b>Public Shareholding</b>						
	i) Number of Shares	2,894,901	2,894,901	2,894,901	2,894,901	2,894,901	2,894,901
	ii) Percentage of shareholding	63.33%	63.33%	63.33%	63.33%	63.33%	63.33%
2	<b>Promoters and promoter group Shareholding</b>						
	<b>a) Pledged/Encumbered</b>						
	I) Number of shares	-	-	-	-	-	-
	II)Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	III)Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	<b>b) Non-encumbered</b>						
	i) Number of Shares	1,676,099	1,676,099	1,676,099	1,676,099	1,676,099	1,676,099
	ii)Percentage of shares (as a % of the total shareholding of promoter and promoter group)	36.67%	36.67%	36.67%	36.67%	36.67%	36.67%
	iii)Percentage of shares (as a % of the total share capital of the company)	100%	100%	100%	100%	100%	100%

					3 MONTHS ENDED 31-12-2015
B	<b>INVESTORS COMPLAINTS</b>				
	i) Pending at Beginning of the Quarter				Nil
	ii) Received During the Quarter				Nil
	iii) Disposed of During the Quarter				Nil
	iv) Remaining at the end of the Quarter				Nil

**NOTES :-**

1. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30-01-2016.
2. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable
- 3) Previous period figures have been regrouped wherever required.

For and on behalf of the Board  
**COLINZ LABORATORIES LTD.**

CIN NO : L24200MH1986PLC041128

MUMBAI.  
30.01.2016

  
**Dr. L. S. MANI**  
(Managing Director.)  
(DIN NO : 00825886)